Trial Profile

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMB 101 IMBiologics (Primary)
Indications Hidradenitis suppurativa
Focus Therapeutic Use
Acronyms Mainsail
Sponsors Navigator Medicines

Most Recent Events

03 Feb 2026 Status changed from planning to recruiting.
08 Jan 2026 According to a Navigator Medicines media release, U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application for NAV-240, phase 2a clinical trial in hidradenitis suppurativa, with patient dosing expected to begin in the first quarter of 2026.
17 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com